Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-16
2005-08-16
Owens, Amelia Averill (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S368000, C544S369000, C514S254020
Reexamination Certificate
active
06930111
ABSTRACT:
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
REFERENCES:
patent: 3642798 (1972-02-01), Furue et al.
patent: 4567264 (1986-01-01), Kluge et al.
patent: 6451798 (2002-09-01), Varkhedkar et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6559162 (2003-05-01), Bjorsne et al.
patent: 6573264 (2003-06-01), Zablocki et al.
patent: 6677343 (2004-01-01), Blackburn et al.
patent: WO 98/21190 (1998-05-01), None
patent: WO 01/19839 (2001-03-01), None
patent: WO 01/62711 (2001-08-01), None
patent: WO 01/62744 (2001-08-01), None
Suzuki T et al: “Structue-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer”, Journal of Chemistry, vol. 40, No. 13, 1997, pp. 2047-2052, XP000924067, the whole document, particularly p. 2049, table 2, compound 5.
Zacharowski K et al: “Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.” European Journal of Pharmacology, vol. 418, No. 1-2, Apr. 20, 2001, pp. 105-110, XP002215620, the whole document.
Lopaschuk G D: “Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism”, The American Journal of Cardiology, vol. 82, No. 5A, Sep. 3, 1997, pp. 14K-17K, XP002215621, the whole document.
Berthold, R. et al ‘3-Aminopropoxyarl derivatives’ CA 105:172505 (1986).
Fan, Y. et al ‘Syntheses of 1-(2-hydroxy-3-aryloxypropyl)-4-aryolpiperazines’ CA 108:5971 (1988).
Singh, RB et al ‘Association of central obesity of insulin resistance with high prevalance of diabetes and cardiovascular disease in an elder population with low fat intake and lower than normal prevalence of obesity: the Indian paradox’ (1999) DubMed ID: 9861517.
Taylor, JA et al ‘Estrogen receptor mutations’ Molecular and Cellular Endocrinology 145 (1998) 61-66.
Elzein Elfatih
Ibrahim Prabha
Palle Venkata
Rehder Kenneth S.
Shenk Kevin
Clarke Pauline Ann
CV Therapeutics Inc.
Hartman J. Elin
Lewis Brian
Owens Amelia Averill
LandOfFree
Substituted heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459317